



Investor Presentation

February 2024

Important Information

Important Notice

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Mithra Pharmaceuticals SA (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation:

- This presentation has been prepared by the management of the Company. It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company and the nature of its securities before taking any investment decision with respect to securities of the Company. Risk factors which are likely to have a material effect on the Company's business are presented in the Company's annual report for the year ended 31 December 2022, published on 18 April 2023 and available on the Company's website (www.mithra.com). An investment in the Company is suitable only for investors who understand the risk associated with this type of investment and who can afford a loss of all or part of their investment. This presentation is not a prospectus or offering memorandum.
- The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation or undertaking to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.
- The presentation also contains information from third parties. Third party industry publications, studies and surveys may also contain that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company, or any of their respective parent or subsidiary undertakings or affiliates, or any of their respective directors, officers, employees, advisers or agents have independently verified the data contained therein. Thus, while the information from third parties has been accurately reproduced with no omissions that would render it misleading, and the Company believes it to be reliable, the Company cannot guarantee its accuracy or completeness. In addition, certain of the industry and market data contained in this presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this presentation.
- This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.
- This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.
- This presentation is not an offer for securities in the United States. The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.
- By attending a meeting where this presentation is presented or by accepting a copy of it, you agree to be bound by the foregoing limitations.

Regulatory disclaimer:

- Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium.

General disclaimer:

- Mithra Pharmaceuticals is closely following the evolution of macroeconomic conditions, the geopolitical situation in Ukraine and the COVID-19 global health crisis and is in constant dialogue with its partners to assess the impact and adapt operations accordingly.
- Mithra Pharmaceuticals has put in place mitigation plans to minimise delays. The impact of increased demands on the healthcare systems, limitations on non-essential hospital visits and procedures, social-distancing and travel restrictions may result in further delays to execution of clinical studies and impact sales.
- Mithra Pharmaceuticals will continue to update the market as needed and whenever possible.

Note:

- ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Achievements to date-- 2023

May

- EUR 12.5 million in financing from Highbridge/Whitebox

June

- EUR 10 million in cash from our sale of Mayne Pharma shares
- Positive preclinical data for CSF-1R tyrosine kinase inhibitors

July

- EUR 17.05 million Canadian binding term sheet for DONESTA® with Searchlight Pharma

August

- EUR 20 million equity private placement with Armistice Capital (with up to EUR 45 million more possible)
- API Supply agreement for Estetrol (E4) native estrogen with Gedeon Richter
- EUR 1.25 million milestone payment from Fuji Pharma, ESTELLE® Japan partner

October

- EUR 1.5 million milestone payment from Searchlight for execution of Canadian agreement
- EUR 2.5 million milestone payment from Fuji Pharma, ESTELLE® Japan partner

November

- FDA recommends DONESTA® for full US market authorization
- NEXTSTELLIS® (ESTELLE®) granted additional US patent until 2036

December

- EUR 5.7 million initial milestones deal with Gedeon Richter for DONESTA® and ESTELLE® in China
- Mithra is eligible to receive a total of EUR 2.05 million sales-related milestones, along with tiered double-digit royalties on annual net sales



Cash inflows from partnerships

Product	Regional marketing partners	Total upfront & milestone payments to date (EUR)	Total potential future milestones (EUR) ¹	Total royalty &/or supply cash in from inception to date (H1 2023) (EUR)
ESTELLE®	15	128 million	296 million	21 million
DONESTA®	2	55 million	32 million	0 million
MYRING®	20	12 million	0 million	9 million
Total	--	198 million	328 million	30 million

¹ additional potential upside of high single-digit to low double-digit per annum royalties based on sales

Strategic priorities

ESTELLE®

- Support marketing partners to realize growth potential
- Continued clinical development to support product differentiation

DONESTA®

- Complete NDA filing with FDA
- Establish optimal U.S. marketing agreement
- Perform additional clinical Phase 2 studies
- Hair
- Skin
- Sexual desire

Estetrol (E4)

- New indications in women's health for fertility
- IVF implantation exploratory clinical studies on endometrial thickening
- New pharmacoeconomic Phase 2 and Phase 4 studies
- Estetrol (ESTELLE® / DONESTA®) safety in breast cancer & blood clotting

Additional imperatives

- Debt consolidation
- Better leverage CDMO
- Options for Novalon complex therapeutics business
- Acquire preclinical and/or clinical opportunities

Fundamental strengths for success

New pipeline
next generation
medicines for
women's health

mithra
Women's Health

Innovative
Estetrol-based
products with
important
commercial role
in women's
health

Revenue growth
& strategic
opportunities

- Estetrol; MYRING®;
TIBELIA®;
ZORELINE®
- CDMO

Strong
experienced
management

ESTELLE® U.S.
launch & sales
ramping up
DONESTA®
preparing for
NDA filing

Strong Experienced Management




Chief Executive Officer
David Horn Solomon



Chief Scientific Officer
Graham Dixon



Chief Operating Officer
Xavier Paoli



Chief Commercial Officer
Jean Manuel Fontaine



Chief Financial Officer
Christophe Maréchal




Diversified pipeline offering multiple near-term catalysts


	Product	Indication	Preclinical	Phase I	Phase II	Phase III	Commercialization
Esterol	ESTELLE®	Contraception					
	DONESTA®	Menopause					
	IVF	Fertility					
Novalon	MYRING®	Contraception					
	TIBELIA®	Menopause					
	ZORELINE®	Oncology					



Estetrol

Innovative product portfolio






Estetrol (E4)

a new estrogen with a
differentiated benefit/risk profile

Estetrol: the early-life native estrogen


Estrogens made by the body



Estrogens made outside the body

Synthetic Estrogens
(e.g. *Ethinyl Estradiol*)

Produced for medical use e.g. in birth control pills



Phytoestrogens

Found in plants, E1 e.g. in soybeans



Xenoestrogens


Endocrine disrupting agents coming from man-made products



Estetrol: unique mode of action vs other estrogens

AGONIST on the nuclear ER α


- Activates the **nuclear estrogen receptor**²⁻⁴
- Important estrogenic activity on the **vagina, endometrium, bone and cardiovascular system** to provide beneficial effects²⁻⁴



ANTAGONIST on the membrane ER α

- Blocks the membrane estrogen receptor²⁻⁴
- Neutral effect on the liver unlike other estrogens²⁻⁴
- Low impact on breast tissue (normal and malignant)⁵⁻⁸

A favorable safety profile



- **Similar to other estrogens**, estetrol has also a beneficial and positive impact on the cardiovascular system, brain, bone and endometrium
- **Unlike other estrogens**, estetrol has a limited impact on the liver and breast
- **Breast:** mixed activity on breast cell proliferation, migration and invasion¹, limited impact on breast at therapeutic dose
- **Liver:**
 - minimal impact on Sex Hormone Binding Globulin (SHBG) synthesis
 - minimal impact on synthesis of coagulation factors (lower risk of VTE)
 - limited lipid impact (including Triglycerides)

1. In presence of Estradiol (E2)

Visser et al. *Climacteric* 2008 | Mawet et al. *Eur J Contracept Reprod Health Care* 2015 | Gérard et al. *J Endocrinol* 2015 | Abot et al. *EMBO Mol Med* 2014 | Coelingh Bennink et al. *Climacteric* 2008 | Heegaard et al. *Climacteric* 2008 | Holinka et al. *Biol Reprod.* 1980 | Holinka et al. *Climacteric* 2008 | Pluchino et al. *J Steroid Biochem Mol Biol* 2014 | Tskitishvili et al. *Exp Neurol* 2014 | Guivarc'h et al. *J Am Heart Assoc* 2018 | Kluff et al. *Contraception* 2017 | Douxfils et al. *Contraception* 2020 | Klipping et al. *Contraception* 2021



Reproductive
Years

ESTELLE®

(15mg estetrol / 3mg DRSP)

A New Era in Combined Oral
Contraception (COC)

OBJECTIVE

Optimize women's physiological hormonal balance by combining the best progestin & estrogen according to their profile

The role of female sex hormones in COCs



Estrogens

- Cycle control



Progestins

- Prevent ovulation
- Thicken cervical lining
- Endometrial protection



ESTELLE® – addressing women's unmet need and improving women's contraceptive experience

Improving contraceptive experience

- ❑ Reliable contraceptive efficacy
- ❑ Excellent cycle control¹
- ❑ Proven superiority in comparison to Ethinylestradiol containing COCs
- ❑ Improved quality of life & high user satisfaction
- ❑ Low risk of drug-drug interaction²

Addressing unmet needs

Favorable safety profile

- ❑ Low impact on all markers of coagulation suggest low clotting risk
- ❑ Minimal increase of triglycerides
- ❑ Minimal impact on glucose metabolism
- ❑ Minimal impact on breast tissue expected based on preclinical data³

1) Kaunitz et al., Contraception 2022; Jensen et al., Contraception 2022; Archer et al., JCM 2022

2) Foidart et al., NAMS 2022

3) Gallez et al. Cancers 2021

Key partners for ESTELLE®'s commercialization



GEDEON RICHTER

Europe

Gedeon Richter Plc. is a major pharma. company which product portfolio covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas

With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's healthcare field worldwide




U.S. and Australia

Mayne Pharma is an ASX-listed specialty pharma. company focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines

It has a 40-year track record of innovation and success in developing new oral drug delivery systems

Mithra holds 4.96% of the outstanding shares

ESTELLE®: Global commercialization progress



■ Commercialized ■ LSA signed


Commercialization started in 2021

In 2023 – First launches in:

- Latin America
- Asia
- Middle East
- Ex CIS countries

ESTELLE® in the US: NEXTSTELLIS® highlights

**NEXTSTELLIS® monthly performance metrics
from 2Q-2022 to 2Q-2023**



NEXTSTELLIS® growth is accelerating thanks to new commercial strategy implemented by Mayne in December 2022

- NEXTSTELLIS® has continued to achieve **solid growth during 1H-2023** to date driven by access improvements (Co-Pay) and new targeting strategy implemented by Mayne in December 2022
- **> 314,000 cycles** dispensed since launch in June 2021
> 161,000 cycles dispensed in 6 months since January 2023
> 7,500 weekly cycles from now
- Growth 2Q-2023 vs 1Q-2023 of **NRx +19% and TRx +19%**
RRx expected to improve following patient retargeting initiative in December 2022
- Experienced **WH sales team of 94** (up from 86) able to reach target customers
- Net selling price returning to normal levels
- **Direct-to-Consumer campaign** launched in July 2022 with **GoodRx and TV campaign** launched in February 2023 with other marketing avenues being explored

DONESTA[®]

(estetrol only)

A new era in
Hormone Therapy (HT)



Menopause
years

Hormone Therapy (HT)

Treatment recommended to address **long-term biological changes**, including common symptoms of menopause, that result from declining levels of the natural hormones (estrogen and progesterone) during and after menopause.

HT also helps **to balance estrogen and progesterone** in women around the time of menopause.

Collapsing of HT's use worldwide after the announcement of the first results of the **Women's Health Initiative (WHI) in 2002**, which indicated that HT could have more detrimental than beneficial effects.

Ph2 POC trials to be launched in 2023 in skin quality, hair quality and FSAD



DONESTA[®]: potentially beyond VMS


Clinical Phase	Primary Endpoint	Secondary Endpoint
Phase 3	Estetrol effect on reducing Vaso-Motor Symptom frequency / severity, H & NH* women	Effect on lipids, glucose metabolism, hemostasis parameters, breast density endometrial safety, health-related quality of life, treatment satisfaction and vulvar and vulvo-vaginal atrophy
Phase 2	Estetrol effect on various aspects of Female Sexual and Urogenital Functions	Effect of estetrol on quality of life
Phase 2	Effect of estetrol on skin health, quality and appearance	Effect of estetrol on quality of life and various skin-related endpoints
Phase 2	Effect of estetrol on hair texture, quality and appearance	Effect of estetrol on quality of life and various hair-related endpoints

**Hysterectomized and non-hysterectomized
Published Phase 2 data: Gaspard et al., Menopause 2023 in press; Gaspard et al., Menopause 2020; Douxfils et al., Climacteric 2022*


DONESTA[®]: Gedeon Richter partnership



Seeking for the highest long-term added value for Mithra and Gedeon Richter
Strengthening our long-term partnership



DONESTA[®]: Territories already covered





Novalon


Complex Therapeutics



Mithra



Estetrol
portfolio






CDMO



Next Steps

Advancing our complex therapeutics business

Products	Description	Indication	Opportunity	Status
MYRING® 	Contraceptive vaginal ring (based on etonogestrel/EE/polymers)	Contraception	Circa \$580m* Original product: NUVARING® from Merck	Commercialized
ZORELINE® 	Biodegradable SQ implant (goserelin)	Prostate & breast cancer and benign gynecological indications	Circa \$963m** Original product: ZOLADEX® from AstraZeneca	New formulations assessed via animal PK/PD comparative study for 1 month and 3 months implant
TIBELIA® 	Therapeutic solution for HT composed of tibolone (synthetic steroid)	Menopause	Circa \$117m** Original product: LIVIAL® from Merck	Commercialized

* According to IQVIA, sales are for the 12 months ended June 2022

** Source: IQVIA quantitative market research, Q2 2022



Mithra CDMO



Mithra



Estetrol
portfolio



Novalon





Next Steps

An integrated R&D and manufacturing platform

Specialized pharmaceutical ecosystem, to take products from POC to market

- 15,000 m² state-of-the art facilities
- Dedicated R&D and production areas
- Ability to handle high potent and complex developments
- Pilot, clinical & commercial batches
- GMP Standards compliance



Ideally located, at the intersection of major **European biopharma clusters**

Strategy for the CDMO is to leverage our **unique expertise in polymers** (long-acting, implants, vaginal rings) **and injectables** for high value-added commercial projects and products

Next steps

1

Mithra

2

Estetrol
portfolio

3

Novalon

4

CDMO

5

Next steps

DONESTA®

- Support NDA filing with FDA
- Additional Phase 2 studies to support differentiation for treatment of menopause symptoms
 - Hair
 - Skin
 - Sexual desire

ESTETROL

- New indications in women's health
 - IVF implantation – exploratory clinical studies on endometrial thickening
- New pharmacoeconomic Phase 2 and Phase 4 studies to establish safety of Estetrol (ESTELLE®/DONESTA®) in breast cancer & blood clotting

ZORELINE®

- 1-month & 3-month formulation studies

Contact us

investorrelations@mithra.com



Rue St-Georges 5/7 - 4000 Liège
Tel : +32 (0)4 349 28 22
<https://www.mithra.com/en/investors/>